INTRODUCTION

The Zika virus (ZIKV) was first isolated in 1947 from the blood of a sentinel rhesus monkey in the Zika forest, Uganda (1). It is a flavivirus transmitted by various species of Ae. aegypti mosquito (2,3). The first human infection was reported in 1954 in Nigeria, and only sporadic cases of infection occurred in Southeast Asia and sub-Saharan Africa until the outbreak of 2007 on Yap Island, the Micronesia (4-6). In October 2013, another outbreak started in French Polynesia in the South Pacific where Guillain-Barré syndrome occurring immediately after the viral infection was seen for the first time (7,8). The outbreak of ZIKV is ongoing since March 2015 and it started in Camaçari, Bahia, Brazil (9). Cases of microcephaly have been increasingly reported in association with viral infection in ZIKV-affected areas (10). Accordingly, on February 1, 2016, the World Health Organization (WHO) declared a Public Health Emergency of International Concern. As of December 15, 2016, 58 countries have experienced the outbreak from 2015 onwards. 13 countries have reported evidence of person-to-person transmission and 29 countries or territories have reported microcephaly and other central nervous system malformations potentially associated with ZIKV, or suggestive of congenital infection (11).

The first case of ZIKV infection in Korea was reported in March 2016 (12). By October 2016, 14 patients had been reported; all of the affected patients had visited areas of risk and tested positive in the ZIKV reverse transcriptase polymerase chain reaction (RT-PCR) in blood, urine, or saliva specimens were included. The first Korean case of ZIKV infection was reported in March 2016, and 14 cases had been reported by October 2016. The median age of the patients was 34 years (19–64 years). Ten patients had been exposed in Southeast Asia and 4 in Latin America. Rash was the most common symptom (92.9%; 13/14), followed by myalgia (50.0%; 7/14), and arthralgia (28.6%, 4/14). There were no neurologic abnormalities and none of the patients was pregnant. Results of biochemical tests were normal. Positivity rates of RT-PCR for ZIKV in serum, urine, and saliva were 53.8%, 100.0%, and 83.3%, respectively in the first week of symptoms. In conclusion, 14 patients with ZIKV infections were reported in Korea by October 2016 and all of them had mild clinical symptoms.

Keywords: Zika Virus; Travel; Virus Shedding; Asia, Southeastern; Latin America; Korea
MATERIALS AND METHODS

Patients who had visited risk areas in the 2 weeks before the onset of symptoms and tested positive for ZIKV reverse transcriptase polymerase chain reaction (RT-PCR) in blood, urine, or saliva specimens were included. Risk areas were identified from the Zika situation report of the WHO (11).

Epidemiological evaluations, routine checks for symptoms, and physical examinations were carried out on these patients along with complete blood counts, liver function tests, blood urea nitrogen (BUN)/creatinine measurements and urinalysis. Blood, urine, and saliva samples were collected for the ZIKV RT-PCR; semen samples were collected from male patients. ZIKV RT-PCR of blood, urine, and saliva samples were performed once weekly until the results were negative. After that, the RT-PCR were performed once more a week later. The RT-PCR of semen samples were performed at initial presentation, and 8 weeks after the onset. The RT-PCR was carried out using a commercial kit, the genesig ZIKV polyprotein standard kit (PrimerDesign Ltd., Southhampton, UK), as well as in-house RT-PCR reported by Lanciotti et al. (13).

Ethics statement
The present study protocol was reviewed and approved by the Institutional Review Board of Seoul National University College of Medicine (Reg. No. 1605-057-761). Informed consent was submitted by all subjects when they were enrolled.

RESULTS

From March to October 2016, 14 patients with ZIKV infections were reported in Korea; 11 were male and 3 were female. The median age was 34 years (19–64 years) and most of the patients were in their thirties or forties (Table 1). Ten patients had been exposed in Southeast Asia (5 in the Philippines, 3 in Vietnam, 2 in Thailand) and 4 in Latin America (1 each in Brazil, Dominican Republic, Guatemala, and Puerto Rico); 12 had been temporary visitors and 2 were long-term residents (in the Dominican Republic and Guatemala). Nine of the patients recalled being bitten by mosquitos. The incubation period was estimated to be 0 to 27 days (Table 1). A total of 14 persons were in company with patients and one of them was confirmed to be infected with ZIKV despite being asymptomatic (case 3, Table 1).

Rash occurred in 13 patients (92.9%; 13/14, Table 2), and its median duration was 3 days (2–8 days). It appeared as erythematous eruptions and was distributed over face, trunk, back, upper and lower extremities, and palms (Fig. 1). Myalgia was seen in 7 patients (50.0%), arthralgia in 4 (28.6%), and 3 (21.4%) presented with fever. Conjunctivitis appeared in 2 patients (14.3%), and headache in 1 (7.1%) patient. One patient was asymptomatic. No patients had neurological symptoms and none were pregnant. Blood tests showed no abnormalities in leukocytes.

Table 1. Epidemiologic findings of patients infected with ZIKV in 2016

| Cases | Sex | Age, yr | Exposure site | Travel period | Date of onset |
|-------|-----|---------|---------------|---------------|--------------|
| Case 1 | M   | 44      | Northeast Brazil | 2.17–3.90     | 3.16         |
| Case 2 | M   | 21      | Boracay, the Philippines | 4.10–4.14     | 4.20         |
| Case 3 | M   | 22      | Boracay, the Philippines | 4.10–4.14     | Asymptomatic |
| Case 4 | F   | 26      | Ho Chi Minh City, Vietnam | 4.10–5.10     | 4.19         |
| Case 5 | M   | 39      | Luzon, the Philippines | 4.27–5.40     | 5.70         |
| Case 6 | F   | 28      | The Dominican Republic | *             | 6.27         |
| Case 7 | M   | 52      | Guatemala       | *             | 7.80         |
| Case 8 | M   | 24      | Puerto Rico     | 6.26–7.10     | 7.90         |
| Case 9 | F   | 40      | Ho Chi Minh City, Vietnam | 7.11–7.15     | 7.19         |
| Case 10| M   | 35      | Pattaya, Thailand | 7.31–8.80     | 8.14         |
| Case 11| M   | 54      | Ho Chi Minh City, Vietnam | 8.15–8.19     | 8.25         |
| Case 12| M   | 34      | Calamba City, the Philippines | 8.14–9.60     | 9.90         |
| Case 13| M   | 26      | Calamba City, the Philippines | 9.20–9.13     | 9.60         |
| Case 14| M   | 34      | Bangkok, Thailand | 9.80–9.16     | 9.16         |

ZIKV = Zika virus.

*Long term resident.

Table 2. Clinical manifestations of patients infected with ZIKV (+: positive, −: negative)

| Cases | Rash | Myalgia | Arthralgia | Fever | Conjunctivitis | Headache |
|-------|------|---------|------------|-------|---------------|----------|
| Case 1 | +    | +       | −          | +     | −             | −        |
| Case 2 | +    | −       | −          | −     | −             | −        |
| Case 3 | −    | −       | −          | −     | −             | −        |
| Case 4 | +    | −       | −          | −     | −             | −        |
| Case 5 | +    | +       | +          | −     | −             | −        |
| Case 6 | +    | −       | −          | −     | +             | −        |
| Case 7 | +    | −       | −          | −     | −             | −        |
| Case 8 | +    | −       | −          | −     | −             | −        |
| Case 9 | +    | +       | +          | −     | −             | −        |
| Case 10| +    | −       | −          | −     | −             | −        |
| Case 11| +    | −       | −          | −     | −             | −        |
| Case 12| +    | +       | +          | −     | −             | −        |
| Case 13| +    | −       | −          | −     | −             | −        |
| Case 14| +    | +       | −          | −     | −             | +        |

ZIKV = Zika virus.
red blood cells, and platelet counts and liver enzyme levels. Urinalysis also revealed normal findings.

RT-PCR positivity rates in serum, urine, and saliva were 53.8% (7 out of 13), 100.0% (13 out of 13), and 83.3% (5 out of 6) in the first week of symptoms, respectively (Table 3). In the second week, the positivity rate for RT-PCR in serum fell to zero, while the rates for urine and saliva were 71.4% (10 out of 14) and 57.1% (8 out of 14), respectively. Positivity rates for urine and saliva dropped to 20.0% (2 out of 10) and 16.7% (1 out of 6), respectively, by the third week of symptoms. In the semen specimen RT-PCR was positive up to the 9th week.

It has been reported that the majority of the patients with ZIKV infection are asymptomatic and clinical presentations of symptomatic patients are mild and self-limiting (14). The most common clinical features of ZIKV infection are rash, myalgia, arthralgia, fever, fatigue, and conjunctivitis. Although clinical presentations are mild, ZIKV infection has become a public health concern now because it can cause complications including congenital microcephaly and Guillain-Barré syndrome (7,15). ZIKV transmitted mostly via the bite of infected mosquito. Few cases of person to person sexual transmission have been reported and ZIKV RNA has been detected in semen of infected male. In this study ZIKV RNA was detected in 1 male patient 9 weeks after the onset of symptoms. ZIKV infection should be suspected in clinically compatible patients without travel history, because ZIKV could be transmitted via sexual intercourse with infected partners.

In Asia, ZIKV was first isolated from Aedes aegypti in Malaysia in 1966 and the first human infection was reported in 1977 in Indonesia (3). Until 2013, sporadic isolation was reported among residents in, and travelers to, Southeast Asia, but no definite outbreak occurred (5). Two cases of ZIKV infection imported from French Polynesia were reported in Japan in 2014, and, following the declaration of a ZIKV pandemic in 2016, ZIKV cases were reported in numerous Asian countries such as Taiwan, Indonesia, China, and Vietnam (16). There are 2 major lineages of ZIKV, African and Asian, which were identified by phylogenetic analyses (2,17). The strain which provoked epi-

**DISCUSSION**

A total of 14 patients with ZIKV infections were reported from March to October 2016 in Korea; 10 patients were exposed to the virus in Southeast Asia and 4 in Latin America. All symptomatic patients showed mild degree of illness and there were no neurologic abnormalities. None of the patients was pregnant. All but 1 patient suffered from rash, which was distributed over the face, trunk, upper and lower extremities, and palms. Findings of blood and urine tests were normal. RT-PCR tests of serum samples were positive only in the 1st week after symptom onset, but they were positive in urine and saliva until the 3rd week. In the semen specimen RT-PCR was positive up to the 9th week.

It has been reported that the majority of the patients with ZIKV infection are asymptomatic and clinical presentations of symptomatic patients are mild and self-limiting (14). The most common clinical features of ZIKV infection are rash, myalgia, arthralgia, fever, fatigue, and conjunctivitis. Although clinical presentations are mild, ZIKV infection has become a public health concern now because it can cause complications including congenital microcephaly and Guillain-Barré syndrome (7,15). ZIKV transmitted mostly via the bite of infected mosquito. Few cases of person to person sexual transmission have been reported and ZIKV RNA has been detected in semen of infected male. In this study ZIKV RNA was detected in 1 male patient 9 weeks after the onset of symptoms. ZIKV infection should be suspected in clinically compatible patients without travel history, because ZIKV could be transmitted via sexual intercourse with infected partners.

In Asia, ZIKV was first isolated from Aedes aegypti in Malaysia in 1966 and the first human infection was reported in 1977 in Indonesia (3). Until 2013, sporadic isolation was reported among residents in, and travelers to, Southeast Asia, but no definite outbreak occurred (5). Two cases of ZIKV infection imported from French Polynesia were reported in Japan in 2014, and, following the declaration of a ZIKV pandemic in 2016, ZIKV cases were reported in numerous Asian countries such as Taiwan, Indonesia, China, and Vietnam (16). There are 2 major lineages of ZIKV, African and Asian, which were identified by phylogenetic analyses (2,17). The strain which provoked epi-

---

**Table 3. Positivity rates of RT-PCR for ZIKV in the serum, urine, and saliva of patients**

| Specimens | No. (%) of positive/examined samples |
|-----------|-------------------------------------|
|           | Week 1     | Week 2     | Week 3     | Week 4     |
| Serum     | 7/13 (53.8) | 0/13 (0)   | 0/9 (0)    | -          |
| Urine     | 13/13 (100.0) | 10/14 (71.4) | 2/10 (20.0) | 0/3 (0)   |
| Saliva    | 5/6 (83.3)  | 8/14 (57.1) | 1/6 (16.7) | 0/2 (0)   |

RT-PCR = reverse transcriptase polymerase chain reaction, ZIKV = Zika virus.
demics on Yap Island of the Micronesia and in South America is classified in the Asian lineage (14). On August 27, 2016, the first local transmission of ZIKV in Singapore was identified and the strain appeared later to be of Asian lineage and distinct from that circulating in the Americas (18). In September 2016, the first Asian case of Zika-linked microcephaly was confirmed in Thailand (11).

ZIKV was first isolated from Aedes aegypti in 1948, but Aedes albopictus is the major vector for the virus in Asia and South America (2,19,20). There has been a longstanding suspicion that Aedes albopictus, an important vector for chikungunya fever, might be a vector as well, and the first ZIKV detection in Aedes albopictus was reported in 2014 (19). Since Aedes albopictus is the species found in Korea, concerns about the influx of, and colonization by, ZIKV have been raised (21,22). Although the competence of Aedes albopictus to transmit ZIKV has been reported to be much lower than that of Aedes aegypti, the possibility of ZIKV colonization in Korea needs to be closely monitored (23-25).

In conclusion, 14 patients with ZIKV infection were reported in Korea by October 2016 and all the patients had mild or no clinical symptoms.

ACKNOWLEDGMENT

Patient care, follow-up, and specimen collection were performed in collaboration with the Korea Centers for Disease Control and Prevention. Reverse transcriptase polymerase chain reaction (RT-PCR) for Zika virus was performed at the Division of Arbovirology, Korea National Institute of Health.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Conceptualization: Choi EH, Oh MD, Kim NJ. Data curation: Yoon D, Shin SH, Jang HC, Kim ES, Song EH, Moon SM, Shin SY, Choe PG, Sung JJ, Jee Y. Writing - original draft: Yoon D, Choi EH, Kim NJ.

ORCID

Doran Yoon https://orcid.org/0000-0002-4438-4005
Seung Hwan Shin https://orcid.org/0000-0003-3411-4455
Hee-Chang Jang https://orcid.org/0000-0002-3407-8493
Eu Suk Kim https://orcid.org/0000-0001-7132-0157
Eun Hee Song https://orcid.org/0000-0001-9939-3227
Song Mi Moon https://orcid.org/0000-0003-1241-4895
So Youn Shin https://orcid.org/0000-0002-4242-2805

Pyeong Gyun Choe https://orcid.org/0000-0001-6794-7918
Jung-Joon Sung https://orcid.org/0000-0001-7525-5313
Eun Hwa Choi https://orcid.org/0000-0002-5857-0749
Myoung-don Oh https://orcid.org/0000-0002-2344-7695
Youngmee Je https://orcid.org/0000-0001-5369-6628
Nam Joong Kim https://orcid.org/0000-0001-6793-9467

REFERENCES

1. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952; 46: 509-20.
2. Haddow AJ, Williams MC, Woodall JP, Simpson DJ, Goma LK. Twelve isolations of Zika virus from Aedes (Stegomyia) africanus (Theobald) taken in and above a Uganda forest, Bull World Health Organ 1964; 31: 57-69.
3. Marchette NJ, Garcia R, Rudnick A. Isolation of Zika virus from Aedes aegypti mosquitoes in Malaysia. Am J Trop Med Hyg 1969; 18: 411-5.
4. MacNamara FN. Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria. Trans R Soc Trop Med Hyg 1954; 48: 139-45.
5. Ginier M, Neumayr A, Günther S, Schmidt-Chanasit J, Blum J. Zika without symptoms in returning travellers: what are the implications? Travel Med Infect Dis 2016; 14: 16-20.
6. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pre-trick M, Marfel M, Holzbauer S, Dubray C, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009; 360: 2536-43.
7. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, Baudouin L, Mallet H, Musso D, Guevrekian E. Zika virus infection complicated by Guillain-Barre syndrome—case report, French Polynesia, December 2013. Euro Surveill 2014; 19: 20720.
8. Cao-Lormeau VM, Musso D. Emerging arboviruses in the Pacific. Lancet 2014; 384: 1571-2.
9. Campos GS, Bandeira AC, Sardi SI. Zika virus outbreak, Bahia, Brazil. Emerg Infect Dis 2015; 21: 1865-6.
10. Schuler-Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A, Doriqui MJ, Neri JI, Neto JM, Wanderley HY, et al. Possible association between Zika virus infection and microcephaly - Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016; 65: 59-62.
11. World Health Organization. Zika situation report [Internet]. Available at http://who.int/emergencies/zika-virus/situation-report/15-december-2016/en/ [accessed on 29 December 2016].
12. Jang HC, Park WB, Kim UJ, Choo SI, Choe PG, Jung SI, Jee Y, Kim NJ, Choi EH, et al. First imported case of Zika virus infection into Korea. J Korean Med Sci 2016; 31: 1173-7.
13. Lanciotti RS, Kosoy OL, Laven JJ, Choppin PW, Schnake-Messer TM, Roehrig JT, et al. Zika virus infection associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 2008; 14: 1232-9.
14. Plourde AR, Bloch EM. A literature review of Zika virus. Emerg Infect Dis 2016; 22: 1185-92.
15. Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL, Zika and the risk of microcephaly. N Engl J Med 2016; 375: 1-4.
16. ProMED-mail (US). Zika virus (03): Americas, Asia (28 Jan 2016), ProMED-Mail
17. Haddow AD, Schuh AJ, Yasuda CY, Kasper MR, Heang V, Huy R, Guzman H, Tesh RB, Weaver SC. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. *PLoS Negl Trop Dis* 2012; 6: e1477.
18. Fisher D, Cutter J. The inevitable colonisation of Singapore by Zika virus. *BMC Med* 2016; 14: 188.
19. Grard G, Caron M, Mombo IM, Nkoghe D, Mboui Ondo S, Joëlle D, Fontenille D, Paupy C, Leroy EM. Zika virus in Gabon (Central Africa)—2007: a new threat from *Aedes albopictus? PLoS Negl Trop Dis* 2014; 8: e2681.
20. Woo JJ, Bae JH, Kang JH, Lee KH. Outbreak of Zika virus. *J Bacteriol Virol* 2016; 46: 330-4.
21. Lee SK, Ree HI. Studies on mosquito population dynamics in Cholla-bugdo, Korea (1985–1990) I. Seasonal and annual fluctuations in population size. *Korean J Entomol* 1991; 21: 141-55.
22. Lee SH, Nam KW, Jeong JY, Yoo SJ, Koh YS, Lee S, Heo ST, Seong SY, Lee KH. The effects of climate change and globalization on mosquito vectors: evidence from Jeju Island, South Korea on the potential for Asian tiger mosquito (*Aedes albopictus*) influxes and survival from Vietnam rather than Japan. *PLoS One* 2013; 8: e66512.
23. Di Luca M, Severini F, Toma L, Boccolini D, Romi R, Remoli ME, Sabbatucci M, Rizzo C, Venturi G, Rezza G, et al. Experimental studies of susceptibility of Italian *Aedes albopictus* to Zika virus. *Euro Surveill* 2016; 21: 30223.
24. Chouin-Carneiro T, Vega-Rua A, Vazeille M, Yebakima A, Girod R, Goindin D, Dupont-Rouzyrol M, Lourenço-de-Oliveira R, Failloux AB. Differential susceptibilities of *Aedes aegypti* and *Aedes albopictus* from the Americas to Zika virus. *PLoS Negl Trop Dis* 2016; 10: e0004543.
25. Brady OJ, Golding N, Pigott DM, Kraemer MU, Messina JP, Reiner RC Jr, Scott TW, Smith DL, Gething PW, Hay SI. Global temperature constraints on *Aedes aegypti* and *Ae. albopictus* persistence and competence for dengue virus transmission. *Parasit Vectors* 2014; 7: 338.